BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND ER, estrogen receptor AND Staging
26 results:

  • 1. To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma.
    Yadav A; Sistla A; Swain M; Gowrishankar S; Padua M; Modi T; Himabindu R; Agarwal N; Kulkarni A; Bhandari T; Vudayaraju H; Chinnababu ; Reddy VA
    Indian J Pathol Microbiol; 2024; 67(1):62-67. PubMed ID: 38358190
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
    Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
    Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. ovarian Mesonephric-Like Adenocarcinoma With Recurrent Liver Metastases: A Case Report with Analysis of Therapeutic Molecular Targets.
    Sugitani A; Ogawa A; Yoshida H; Kobayashi-Kato M; Kikkawa N; Tanase Y; Uno M; Ishikawa M; Kato T
    Int J Surg Pathol; 2024 May; 32(3):578-585. PubMed ID: 37345348
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
    Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
    Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
    [No Abstract]    [Full Text] [Related]  

  • 5. Primary Breast Carcinoma of the Vulva Metastatic to Lymph Nodes and Bones: A Case Report and Literature Review.
    Ananthula A; Lockwood B; Savage J; Malak S; Chen C; Makhoul I; Pennisi A
    Perm J; 2020; 24():. PubMed ID: 32097114
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Comparison of E-cadherin with STAT3 and apoptosis regulators: Bak and Bcl-xL in endometrioid adenocarcinomas of different ER-alpha immunoprofile.
    Sulkowska U; Wincewicz A; Kanczuga-Koda L; Koda M; Sulkowski S
    Gynecol Endocrinol; 2018 Feb; 34(2):171-174. PubMed ID: 28937296
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of ovarian Serous Carcinoma.
    Chapel DB; Husain AN; Krausz T; McGregor SM
    Am J Surg Pathol; 2017 Dec; 41(12):1675-1682. PubMed ID: 28877056
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
    Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
    Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Morphological, imaging and surgical aspects in endometrial endometrioid adenocarcinoma.
    Berceanu C; Stepan AE; MehedinŢu C; Cîrstoiu MM; Ciortea R; Berceanu S; Gheonea IA; Brătilă E
    Rom J Morphol Embryol; 2016; 57(3):995-1002. PubMed ID: 28002515
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Falk RT; Staff AC; Bradwin G; Karumanchi SA; Troisi R
    Cancer Causes Control; 2016 Aug; 27(8):1009-17. PubMed ID: 27357932
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Metastatic large cell neuroendocrine carcinoma of the lung arising from the uterus: A pitfall in lung cancer diagnosis.
    Ono K; Yokota NR; Yoshioka E; Noguchi A; Washimi K; Kawachi K; Miyagi Y; Kato H; Yokose T
    Pathol Res Pract; 2016 Jul; 212(7):654-7. PubMed ID: 27113439
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Incidental Pelvic and Para-aortic Lymph Node Lymphangioleiomyomatosis Detected During Surgical staging of Pelvic cancer in Women Without Symptomatic Pulmonary Lymphangioleiomyomatosis or Tuberous Sclerosis Complex.
    Rabban JT; Firetag B; Sangoi AR; Post MD; Zaloudek CJ
    Am J Surg Pathol; 2015 Aug; 39(8):1015-25. PubMed ID: 25786086
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Clinical significance of FIGO 2009 staging I and its prognostic related factors in endometrial carcinoma].
    Zhou J; Zhao L; Qi W; Li X; Wang J; Wei L
    Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):776-9. PubMed ID: 25537252
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases.
    Yoon A; Park JY; Park JY; Lee YY; Kim TJ; Choi CH; Bae DS; Kim BG; Lee JW; Nam JH
    Gynecol Oncol; 2014 Jan; 132(1):70-5. PubMed ID: 24184602
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immunohistochemical expression of ERα, ERβ, and TFF1 in type I and II ovarian tumors.
    Abdou AG; Aiad HA; Asaad NY; Abd El-Wahed MM; Serag El-Dien M
    Appl Immunohistochem Mol Morphol; 2014 Jul; 22(6):421-32. PubMed ID: 24162262
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas.
    Zhang Y; Garcia-Buitrago MT; Koru-Sengul T; Schuman S; Ganjei-Azar P
    Int J Gynecol Pathol; 2013 Sep; 32(5):476-81. PubMed ID: 23896709
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.